Physician profile
Nathan Strandmark
NPI 1457428518
$3,890.16
in general payments reported to CMS, 2019-2025
47 companies · $1,530 in 2025
The $1,530 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.51 · 2021: $257 · 2022: $914 · 2023: $509 · 2024: $658 · 2025: $1,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,697.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $670.97 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $422.04 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $273.23 | 2022-2025 | |
| Abbvie INC. | $259.61 | 2022-2025 | |
| Lilly USA, LLC | $188.82 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.45 | 2022-2025 | Jardiance, Ofev |
| Dexcom, INC. | $164.56 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $148.85 | 2022-2025 | Repatha, Otezla, Otezla |
| Mylan Specialty L.P. | $142.21 | 2021-2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.81 | 2021-2024 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $117.26 | 2021-2022 | |
| Lundbeck LLC | $86.66 | 2025 | Rexulti |
| Astellas Pharma US INC | $79.04 | 2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.72 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $74.55 | 2024-2025 | Cologuard Collection Kit |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Strandmark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.